Wisevoter
U.S.

Takeda Wins FDA Nod for Orexin Narcolepsy Drug

The approval marks the first orexin agonist cleared for Type 1 narcolepsy as rivals race into the emerging market.

Updated on Nov. 2, 2026 in Healthcare

Clear glass laboratory vessels holding pale amber liquid on a steel bench in front of a modern research building's glass wall.
Takeda received FDA approval for orexin, the first orexin agonist cleared for Type 1 narcolepsy, as Eli Lilly moves into the market with its roughly $6.3 billion Centessa acquisition. AI Illustration. Upload story photo >

Takeda Pharmaceuticals has received FDA approval for orexin, the first agonist drug approved for Type 1 narcolepsy. The approval comes as Eli Lilly moves into the orexin market with its roughly $6.3 billion acquisition of Centessa Pharmaceuticals.

Why it matters

Orexin targets the neuropeptide system that regulates wakefulness, offering a mechanism-based option for patients with excessive daytime sleepiness. Competitive entry from Eli Lilly and others signals that the orexin agonist category is becoming a significant commercial battleground.

Eli Lilly's roughly $6.3 billion purchase of Centessa Pharmaceuticals in March 2026 signals the financial stakes in orexin drugs. Harmony's Wakix, its only approved product, reached over $261 million in second-quarter 2026 net product revenue, up 30% year over year, though pricing and launch details for orexin remain unreported.

The players

Takeda Pharmaceuticals

Japan-based drugmaker that received FDA approval for orexin, a treatment for Type 1 narcolepsy.

Eli Lilly

Large U.S. pharmaceutical company that acquired Centessa Pharmaceuticals to enter the orexin market.

Alkermes

Biopharmaceutical company developing alixorexton, which it is evaluating in a global Phase 3 program for narcolepsy.

Harmony Pharmaceuticals

Company behind Wakix, its only approved product, and a developer of the orexin agonist BP-205.

The details

Orexins are neuropeptides secreted by neurons in the hypothalamus, and clinical data from narcolepsy trials showed that boosting them reduces excessive sleepiness. Alkermes has started a global Phase 3 program for alixorexton in Type 1 and Type 2 narcolepsy, after early data showed it kept Type 2 patients awake significantly more effectively than placebo.

Timeline

  1. March 2026: Eli Lilly completes its acquisition of Centessa Pharmaceuticals for roughly $6.3 billion.

  2. Second quarter of 2026: Wakix reports over $261 million in net product revenue.

Market Landscape

Orexin agonists arrive in a narcolepsy market where Harmony's Wakix already generates over $261 million per quarter, shifting competition toward mechanisms that target the orexin system directly. Eli Lilly's $6.3 billion Centessa deal and Alkermes' Phase 3 program suggest rivals are positioning to contest this newly defined category.

Patients with narcolepsy may gain a new treatment option that targets the orexin pathway rather than relying solely on existing stimulants or histamine-based drugs. Availability, pricing, and insurance coverage for orexin have not been detailed in the source material, so patients should confirm access with their prescribers.

The takeaway

Orexin's approval and the rapid entry of Eli Lilly, Alkermes, and Harmony suggest narcolepsy treatment is moving toward mechanism-specific therapies. Readers tracking the sector should watch Phase 3 outcomes and launch pricing as the category matures.

Further reading

For broader context on drug development and approvals, explore Healthcare coverage.